A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
QUEENSBURY, N.Y. - Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following upcoming investor conferences: BTIG...
QUEENSBURY, N.Y. - Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 5, 2024, at 4:30 PM Eastern Time to discuss...
NEW YORK - Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's...
Conference Call Today at 8:30 am Eastern Time QUEENSBURY, N.Y., May 14, 2024 -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
QUEENSBURY, N.Y., May 7, 2024 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 14, 2024, at 8:30 AM Eastern Time...
Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%) Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate NEW YORK, May 6, 2024 -- Delcath Systems, Inc. (Nasdaq: DCTH), an...
NEW YORK, May 3, 2024 -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously...
NEW YORK, April 4, 2024 -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously...
Increases 2024 Treatment Site Activation Guidance to 20 Sites QUEENSBURY, N.Y., March 26, 2024 -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
NEW YORK, March 20, 2024 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, confirmed the closing of the previously announced private placement with certain accredited...